CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Seeking Alpha Healthcare
High ImpactOriginal article

Jazz forecasts $4.60B-$4.75B 2026 revenue as it prepares for Aug. 25 zanidatamab PDUFA

FDA DecisionzanidatamabNeutral
AI Analysis

Summary

Jazz Pharmaceuticals forecasts 2026 revenue of $4.60B-$4.75B and prepares for an August 25, 2026 PDUFA decision on zanidatamab.

Financial Highlights

Guidance

$4.60B-$4.75B 2026 revenue

Importance:8/10
Sentiment:
0.00
PDUFArevenue_guidanceregulatory_milestone
Related Companies

Read the original article

Published by Seeking Alpha Healthcare on August 4, 2026 1:10 AM

Read Original